論文 - 木内　謙一郎

Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension

Kinouchi, K. and Ichihara, A. and Sakoda, M. and Kurauchi-Mito, A. and Itoh, H.

Hypertension Research （Springer Science and Business Media LLC）  32 （ 12 ） 1143 - 1147 2009年12月

筆頭著者, 最終著者, 責任著者, 査読有り,  ISSN  0916-9636

　概要を見る

This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension. Thirty consecutive Japanese diabetic patients with hypertension were randomly assigned to group A, receiving losartan alone for the first 3 months, then L/HCTZ for the next 3 months, or group B, receiving L/HCTZ for the first 3 months, then losartan alone for the next 3 months. Clinical and biological parameters were obtained before, and 3 and 6 months after the start of this study. The decreases in systolic and diastolic blood pressure (BP) during treatment with L/HCTZ were significantly greater than in treatment with losartan alone. Both treatments significantly and similarly decreased urinary albumin excretion, the cardio-ankle vascular index (CAVI) and augmentation index (AI). There was no significant difference in metabolic change during both the mono- and combination pharmacotherapies. The tablet combining L/HCTZ significantly reduced systolic and diastolic BP compared with the losartan monotherapy, and offered benefits similar to losartan monotherapy for albuminuria, arterial stiffness assessed by the CAVI and AI, and metabolic effects. Thus, the L/HCTZ tablet could be a useful drug for Japanese diabetic patients with hypertension.

• Access to Document (DOI)
• CiNii Research

Cell signalling and cell growth control - 2

Rui Ding, Yih-Shou Hsieh, Mohamed Samai, José M. López-Novoa, Adriana Dusso, Shigeyoshi Oba, Silvia Berra, Ying-Sui Sun, Fabien Tourrel, Luís Coentrão, Dominique Guerrot, Wanja Bernhardt, Sandra M. Sancho-Martinez, Kai-Uwe Eckardt, Christina Warnecke, Prabal K. Chatterjee, Nan Chen, Jochen Reiser, Weiping Liu, Kunimasa Yan, Yuanmeng Jin, Thomas Hackenbeck, Alina Mihaela Sburlan (Stanigut), Moin A. Saleem, Toshiro Fujita, Jiri Moravec, Yaremi Quiros, Yasunobu Hirata, Atushiro Ichihara, Victoriya A. Rufanova, Maria Pia Rasaldi, Deborah Mattinzoli, Masayuki Yoshida, Olga Surdu, Biju Marath, Sandra M. Sancho-Martínez, Piergiorgio Messa, Anna Greka, Ondrej Hes, Deborah Jane Mason, Daniel Álvarez-Hernández, Daniela Riccardi, Jan Mares, Maria Vittoria Arcidiacono, Wen Chih Chiang, Dianne Z. Hillyard, Sandra Mattauch, Kyung Pyo Kang, Thorsten Cramer, Sung Kyew Kang, Alejandro Esteller, Maria Pia Rastaldi, Martin Sachs, Maki Sunada, Bo Fu, Michael Wiesener, Andrey Sorokin, Duk Hoon Kim, João S. Amaral, Sung Kwang Park, Kerstin Amann, Doina Tofolean, Patrício Soares-da-Silva, Masanori Tokumoto, Alessandro Corbelli, Carole Elford, Yoshihiro Akimoto, Florea Voinea, Yukino Nishibori, Horng-Rong Chang, Yu Jin Jung, Alan G. Jardine, Christoph Wehrbein, Elias N. Katsoulieris, Tatusya Narita, Xue-Yuan Bai, Anna Alexanian, Ryota Kurayama, Falei Zheng, Masami Ikehata, Irene C. Green, Fang Zhong, Liliana Tuta, Won Kim, Lavinia Voineagu, Laura Giardino, Jung Eun Lee, Hideyuki Negoro, Johannes Schoedel, Arnolt J. Ramos, Wanja M. Bernhardt, Omar García-Sánchez, Ya Li, Kosaku Nitta, Sang Yong Lee, Manal J. Natto, Bronwen Alice James Evans, Michael S. Wiesener, Karl X. Knaup, Yingjuan Zhang, Ray K. Wan, Ae Sin Lee, Jun Ino, Milan Stengl, Min Li, Hui Chen, Maria João Pinho, Hiroshi Itho, Li Zhuo, Nadine Rohwer, Jong-Da Lian, Etsu Suzuki, Alena Hricinova, Cristina Zennaro, Shun-Fa Yang, Kenichiro Kinouchi, Jing Yang, Sik Lee, Guangyan Cai, Rebeca Nunez-Lozano, Yongxi Chen, Silvia Armelloni, Xiangmei Chen, Noriko Ito, Lin Han, Mariyo Sakoda, Weiming Wang, Francisco J. López-Hernández, Yaoguo Lian, Jon G. Mabley, Juergen Behrens, Chiari Kojima, Michele Carraro, Asako Kurauchi-Mito, Quan Hong

NDT Plus （Oxford University Press (OUP)）  2   ii1 - ii1 2009年01月

筆頭著者, 最終著者, 責任著者,  ISSN  17530784

• Access to Document (DOI)
• CiNii Research

Drug discovery for overcoming chronic kidney disease (CKD): New therapy for CKD by a (pro)renin-receptor-blocking decoy peptide

Ichihara, A. and Sakoda, M. and Kurauchi-Mito, A. and Narita, T. and Kinouchi, K. and Itoh, H.

Journal of Pharmacological Sciences 109 （ 1 ） 20 - 23 2009年01月

筆頭著者, 最終著者, 責任著者, 査読有り,  ISSN  1347-8613

• Access to Document (DOI)

Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan

Kaneshiro, Y. and Ichihara, A. and Sakoda, M. and Kurauchi-Mito, A. and Kinouchi, K. and Itoh, H.

Kidney and Blood Pressure Research （S. Karger AG）  32 （ 1 ） 51 - 58 2009年

筆頭著者, 最終著者, 責任著者, 査読有り,  ISSN  1420-4096

　概要を見る

<jats:p>Hypertension frequently requires combination therapy to attain efficient control to prevent cardiovascular diseases effectively. This study was conducted to determine which add-on treatment is better, namely calcium channel blockers or diuretics, in improving vascular damage. In 70 nondiabetic chronic kidney disease stage 1/2 patients who had been already treated with angiotensin II type 1 receptor blocker valsartan for at least 12 months, amlodipine or hydrochlorothiazide was added to their existing medication. Pulse wave velocity (PWV), intima-media thickness (IMT) of the carotid arteries, urinary albumin excretion (UAE), and 24-hour ambulatory blood pressure (BP) were determined before and 12 months after the start of add-on treatments. Add-on amlodipine and add-on hydrochlorothiazide significantly and similarly decreased 24-hour ambulatory BP by 18 and 19 mm Hg, respectively, PWV by 206 and 184 cm/s, respectively, and UAE, but did not change the IMT. The decreases in BP significantly contributed to the decreases in PWV and UAE and suggested that the decrease in serum cholesterol level brought about by add-on amlodipine also contributed to the decrease in UAE. These results suggest that 12 months of add-on treatment with either amlodipine or hydrochlorothiazide could have beneficial effects in nondiabetic chronic kidney disease stage 1/2 patients already being treated with valsartan.</jats:p>

• Access to Document (DOI)
• CiNii Research

Association of (Pro)renin receptor mRNA expression with angiotensin-converting enzyme mRNA expression in human artery

Takemitsu, T. and Ichihara, A. and Kaneshiro, Y. and Sakoda, M. and Kurauchi-Mito, A. and Narita, T. and Kinouchi, K. and Yamashita, N. and Itoh, H.

American Journal of Nephrology （S. Karger AG）  30 （ 4 ） 361 - 370 2009年

筆頭著者, 最終著者, 責任著者, 査読有り,  ISSN  0250-8095

　概要を見る

<jats:p><i>Background/Aims:</i> A significant role of (pro)renin receptor in the pathogenesis of end-organ damage has been suggested only in animal studies. This study was conducted to examine the mRNA expression of (pro)renin receptor in human artery. <i>Methods:</i> In 141 kidney failure patients, the mRNA was harvested from arterial fragments obtained during surgery constructing an arteriovenous access for hemodialysis therapy, and expression levels of (pro)renin receptor and other components of the renin-angiotensin system were determined. <i>Results:</i> Arterial (pro)renin receptor expression was similar in diabetic and non-diabetic patients, although plasma prorenin levels were significantly higher in the diabetic patients than in the non-diabetic patients. The arterial (pro)renin receptor mRNA levels of the hypertensive patients, who had not been treated with either angiotensin-converting enzyme (ACE) inhibitors or angiotensin II type 1 receptor blockers, were significantly lower than those of the patients who had been treated with either drug. Multiple regression analyses showed a significant association with a large coefficient between the arterial mRNA level of the (pro)renin receptor and the arterial mRNA level of ACE; this significant association disappeared in patients who had been treated with either drug. <i>Conclusion:</i> (Pro)renin receptor may contribute to the generation of arterial angiotensin II in kidney failure patients.</jats:p>

• Access to Document (DOI)
• CiNii Research